Skip to content
KStart free
AI InfrastructureDefenseQuantumAll studies →

A Study to Evaluate the Long-term Safety, Tolerability, and Efficacy of Subcutaneous Sonelokimab in Participants With Psoriatic Arthritis

← catalyst calendar

NCT07223138 · readout in 534 d

Sponsored by MoonLake Immunotherapeutics AG (industry) · MLTX — their whole pipeline →.

Phase
Phase 3
Status
Enrolling by invitation
Study type
Interventional
Design
Na · None · Treatment
Enrollment
1,560estimated
Sites
16
Country
United States

Every value on this page is a field the sponsor filed with ClinicalTrials.gov, reproduced. Dates are their own estimates, revised as a study runs, unless the registry marks them actual. sources →

Source: ClinicalTrials.gov, retrieved 2026-08-19

Dates

each axis at the precision it was filed, with the registry's own basis
DateFiledBasisWhat it is
Start2025-11-13actualWhen the study began enrolling
Primary completion2028-02-04estimatedThe date the last participant is measured for the primary outcome — the readout window
Study completion2028-02-04estimatedThe whole study's end, after follow-up
First posted2025-10-31actualWhen this record first appeared on the registry
Results postedWhen the sponsor posted results to the registry
Record updated2026-06-11actualThe sponsor's own last edit to this record — every projection above is as current as this date

What it studies

Condition

  • Arthritis, Psoriatic

Intervention

  • Drug: Sonelokimab

Primary outcomes

what the primary-completion date above is the date OF
Long-term safety and tolerability of sonelokimab:
measured 52 weeks
Long-term safety and tolerability of sonelokimab:
measured 52 weeks
Long-term safety and tolerability of sonelokimab:
measured 52 weeks
Long-term safety and tolerability of sonelokimab:
measured 52 weeks
Long-term safety and tolerability of sonelokimab:
measured 52 weeks
Long-term safety and tolerability of sonelokimab:
measured 52 weeks

Permalink · MLTX's whole pipeline · Catalyst calendar · Every registered study · What changed